US EditionThe Preserve Access to Affordable Generics and Biosimilars Act: It’s Back! And Bigger and Bolder than Before!
Summary by FDA Law Blog
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
The Preserve Access to Affordable Generics and Biosimilars Act: It’s Back! And Bigger and Bolder than Before!
Last week, U.S. Senators Amy Klobuchar (D-MN) and Chuck Grassley (R-IA) announced the introduction of two bills we’ve seen before: (1) S. 1096, the Preserve Access to Affordable Generics and Biosim…
What’s new in the fight for PBM reform and access to biosimilars
Our members in clinical practice continue to be negatively impacted by pharmacy benefit managers (PBMs) formulary placement practices of paying certain biosimilars at rates lower than the practice acquisition cost.This leaves GI practices “underwater,” and forces them to stop infusions. It is ultimately detrimental to patient care when stable IBD patients are forced to switch therapies. This is unacceptable. …
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
